HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacokinetics of nateglinide enantiomers and their metabolites in Goto-Kakizaki rats, a model for type 2 diabetes mellitus.

Abstract
The pharmacokinetics of (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (nateglinide) and its enantiomer (L-enantiomer) was studied in Goto-Kakizaki (GK) rats after intravenous administration of nateglinide or L-enantiomer at a dose of 40 micromol/kg body weight. Nateglinide, its L-enantiomer and their metabolites in serum, bile and urine were determined. The total clearance (CL(tot)) and the volume of distribution (Vd) was slightly higher for nateglinide than those for L-enantiomer in control rats, although the differences were not statistically significant. The cumulative excretions of L-M1 (major metabolite of L-enantiomer) and L-M2 (major metabolite of L-enantiomer) into bile were almost the same as that of M1 (major metabolite of nateglinide)and M2 (major metabolite of nateglinide). In GK rats, CL(tot) and Vd were higher for nateglinide than those for L-enantiomer. The cumulative excretion of L-M1 and L-M2 were not different from those of M1 and M2, respectively, into bile or urine. CL(tot) and Vd for nateglinide or L-enantiomer in GK rats were not different from those in control rats. The total excretion of M1, M2, L-M1, and L-M2 into bile or urine in GK rats was not substantially different from that of control rats. These results suggest that the L-enantiomer of nateglinide shows higher CL(tot) and Vd compared with nateglinide, especially in the diabetic state.
AuthorsMasafumi Tamura, Sachiko Shiba, Naomi Kudo, Yoichi Kawashima
JournalChirality (Chirality) Vol. 22 Issue 1 Pg. 92-8 (Jan 2010) ISSN: 1520-636X [Electronic] United States
PMID19387990 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2009 Wiley-Liss, Inc.
Chemical References
  • Cyclohexanes
  • Hypoglycemic Agents
  • Nateglinide
  • Phenylalanine
Topics
  • Animals
  • Cyclohexanes (chemistry, pharmacokinetics, therapeutic use)
  • Diabetes Mellitus, Type 2 (drug therapy, metabolism)
  • Disease Models, Animal
  • Hypoglycemic Agents (chemistry, pharmacokinetics, therapeutic use)
  • Male
  • Nateglinide
  • Phenylalanine (analogs & derivatives, chemistry, pharmacokinetics, therapeutic use)
  • Rats
  • Rats, Wistar
  • Stereoisomerism

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: